Aflac (AFL) Stock Forecast & Price Target

Aflac is supported by a stronger portfolio mix after repositioning about $4.8 billion of investments, which is expected to add over $50 million of annualized pre-tax net investment income while improving asset-liability management and reducing risk. The outlook is also reinforced by capital-efficient Japan liability ceding that could rise from 10% to about 30% over time and free roughly $2.5 billion of capital, alongside confidence in a 60% to 63% Japan benefit ratio range. In addition, steady U.S. persistency of 79.3%, stable recruiting at about 10,000 to 11,000, and expanding cross-sell of cancer and medical products suggest durable distribution and earnings power that remain underappreciated.

Aflac is facing a weakening fundamental backdrop because its latest quarter was modestly worse than expected, with reported EPS of $1.75 versus consensus of $1.80 and segment earnings missing across Aflac Japan and Aflac U.S.. Japan’s higher-than-expected benefit ratio and concerns that organic growth may be nearing a ceiling, combined with U.S. net earned premiums that fell 2.1% and are expected to land below the 3% to 6% guidance range, point to softer core momentum. Although net investment income rose to $956 million and run-rate EPS was about $1.84 after adjustments, management’s near-term focus on profitability and expected slightly negative corporate pretax earnings suggest limited upside from the current operating mix.